Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study gathers information from the blood cells and tumor tissue during treatment with anti-HER2 therapies, such as trastuzumab, pertuzumab, lapatinib, or neratinib, in patients with HER2 positive stage I-IV breast cancer who are scheduled to start anti-HER2 therapy. The information gained from this study may help researchers better understand the relation between cell response and anti-HER2 therapies.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Osoby powyżej 18 roku życia.
- •Potwierdzony rak piersi w stadium od I do IV.
- •Rak piersi musi być HER2-dodatni (niezależnie od statusu receptorów ER/PR).
- •Zgoda na udział w badaniu i pobranie próbek krwi/tkanki.
- •Pacjentki rozpoczynające nowe leczenie celowane HER2.
- •Pacjentki, które już otrzymywały lub zakończyły leczenie celowane HER2 (tylko grupa badająca tkankę).
✗ Disqualifies
- •Osoby z obniżoną odpornością, w tym zakażone HIV.
- •Przyjmowanie leków immunosupresyjnych (np. sterydów ogólnoustrojowych) w ciągu ostatnich 30 dni przed rozpoczęciem badania (chyba że są to niskie dawki lub leki wziewne).
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- June 16, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
Mayo Clinic in Florida
Jacksonville, United States
Trial contact
Clinical Trials Referral Office
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.